|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
3M Pharmaceuticals (MMM) Announces Long-term Clinical Benefits Of Aldara Cream For Actinic Keratosis
6/20/2005
ST. PAUL, Minn.--(BUSINESS WIRE)--June 20, 2005--
- Majority of Patients Had No Recurrence or New AK Lesions One and One-half Years Post-treatment -
According to a recent study published in the June issue of Dermatologic Surgery, prescription Aldara (imiquimod) cream, 5% delivers long-term clinical benefits in the treatment of actinic keratosis (AK), a precancerous skin condition caused by chronic sun exposure. Led by an investigator at the University of Minnesota, the study showed 75 percent of patients treated with Aldara Cream three times per week, and nearly 60 percent treated two times per week, continued to demonstrate complete clearance of AK after a follow-up period of 12 to 18 months. The first immune response modifier (IRM) approved for AK, Aldara cream stimulates the skin's immune response, which may help decrease formation of recurrent or new AKs.
|
|
|
|
|
|
|
|
|
|
|
|